Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
45
ASMB Quote, Financials, Valuation and Earnings
Last price:
$34.00
Seasonality move
:
7.77%
Day range:
$32.00 - $34.13
52-week range:
$7.75 - $39.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.87x
P/B ratio:
2.94x
Volume:
91.4K
Avg. volume:
137.1K
1-year change:
115.53%
Market cap:
$537.9M
Revenue:
$28.5M
EPS (TTM):
-$4.80
Analysts' Opinion
-
Consensus RatingAssembly Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $47.75, Assembly Biosciences, Inc. has an estimated upside of 40.4% from its current price of $34.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $39.00 representing 100% downside risk from its current price of $34.01.
Fair Value
-
According to the consensus of 4 analysts, Assembly Biosciences, Inc. has 40.4% upside to fair value with a price target of $47.75 per share.
ASMB vs. S&P 500
-
Over the past 5 trading days, Assembly Biosciences, Inc. has overperformed the S&P 500 by 5.19% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Assembly Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Assembly Biosciences, Inc. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Assembly Biosciences, Inc. reported revenues of $10.8M.
Earnings Growth
-
Assembly Biosciences, Inc. has grown year-over-year earnings for 12 quarters straight. In the most recent quarter Assembly Biosciences, Inc. reported earnings per share of -$0.72.
Enterprise value:
308.1M
EV / Invested capital:
--
Price / LTM sales:
7.87x
EV / EBIT:
--
EV / Revenue:
8.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.52x
Price / Operating cash flow:
2.67x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$37.1M
Return On Assets:
-30.11%
Net Income Margin (TTM):
-103.65%
Return On Equity:
-67.09%
Return On Invested Capital:
-64.14%
Operating Margin:
-100.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $28.3M | $37.2M | $6.8M | $10.8M | |
| Gross Profit | -$490K | $28.1M | $37.1M | $6.8M | $10.8M | |
| Operating Income | -$75.7M | -$46.4M | -$43.4M | -$11M | -$10.9M | |
| EBITDA | -$75.3M | -$46.3M | -$43.3M | -$10.9M | -$10.9M | |
| Diluted EPS | -$17.14 | -$7.14 | -$4.80 | -$1.51 | -$0.72 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $188.2M | $115.1M | $49.7M | $98.2M | $236.8M | |
| Total Assets | $249M | $121.5M | $51.6M | $100.3M | $240M | |
| Current Liabilities | $14.9M | $15.5M | $7.1M | $41.6M | $53.4M | |
| Total Liabilities | $24.3M | $19.1M | $9.9M | $74.3M | $57.3M | |
| Total Equity | $224.6M | $102.4M | $41.7M | $26M | $182.7M | |
| Total Debt | $4.1M | $918K | $50K | $113K | $2.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$70.2M | $22.9M | -$55.7M | -$15.2M | -$15.1M | |
| Cash From Investing | $37.1M | -$42.8M | -$141.4M | $24.5M | -$158.3M | |
| Cash From Financing | $5.1M | $21.6M | $191.2M | -- | $171.9M | |
| Free Cash Flow | -$70.3M | $22.8M | -$55.8M | -$15.2M | -$15.2M | |
ASMB
Sector
Market Cap
$537.9M
$27.6M
Price % of 52-Week High
85.66%
50.06%
Dividend Yield
0%
0%
Shareholder Yield
-47.27%
-1.55%
1-Year Price Total Return
115.53%
-18.12%
Beta (5-Year)
1.143
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$33.86
200-day SMA
Buy
Level
$21.85
Bollinger Bands (100)
Buy
Level
24.23 - 34.35
Chaikin Money Flow
Sell
Level
-7.3M
20-day SMA
Sell
Level
$34.49
Relative Strength Index (RSI14)
Sell
Level
49.76
ADX Line
Buy
Level
24.01
Williams %R
Neutral
Level
-66.5775
50-day SMA
Buy
Level
$33.73
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
5.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.1572)
Sell
CA Score
(Annual)
Level (-2.9372)
Sell
Beneish M-Score
(Annual)
Level (0.1133)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.9403)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, ASMB has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ASMB average analyst price target in the past 3 months is $47.75.
-
Where Will Assembly Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Assembly Biosciences, Inc. share price will rise to $47.75 per share over the next 12 months.
-
What Do Analysts Say About Assembly Biosciences, Inc.?
Analysts are divided on their view about Assembly Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Assembly Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $39.00.
-
What Is Assembly Biosciences, Inc.'s Price Target?
The price target for Assembly Biosciences, Inc. over the next 1-year time period is forecast to be $47.75 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ASMB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Assembly Biosciences, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASMB?
You can purchase shares of Assembly Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Assembly Biosciences, Inc. shares.
-
What Is The Assembly Biosciences, Inc. Share Price Today?
Assembly Biosciences, Inc. was last trading at $34.00 per share. This represents the most recent stock quote for Assembly Biosciences, Inc.. Yesterday, Assembly Biosciences, Inc. closed at $34.01 per share.
-
How To Buy Assembly Biosciences, Inc. Stock Online?
In order to purchase Assembly Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ASMB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ASMB
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
2.94x
1.81x
Price / LTM sales
7.87x
1.58x
Growth Metrics
ASMB
Sector
Revenue growth
57.62%
4.6%
Earnings growth
52.1%
10.88%
Revenue (5-year growth)
12.31%
6.46%
Earnings forecast
-$0.85
-$0.18
Profitability
ASMB
Sector
Profitability FY 2024
$28.4M
$3.6M
Return on invested capital
-64.14%
-31.84%
Return on assets
-30.11%
-27.96%
Return on equity
-67.09%
-37.63%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Jan
1
Estimated Next Earnings Date
Apr
2
Balance Sheet
ASMB
Sector
Total cash
$232.6M
$26.3M
Short term investments
$73.7M
$25.7M
Total assets
$120M
$78M
Long term debt
$2.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
